Venetoclax in adult acute myeloid leukemia.

Abstract

Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, both as a monotherapy and in combination with other drugs. This novel therapeutic approach has revolutionized the treatment prospects for AML patients with unfavorable prognoses and those who are unable to tolerate intensive chemotherapy. Nevertheless, further investigations are required to establish the optimal dosing, sequencing, and combinational strategies of venetoclax for AML treatments. Additionally, identifying biomarkers is crucial for predicting response and resistance to this targeted intervention. In this review, we provide an overview of venetoclax-based therapy for AML and explore potential avenues for future research.

• Authors: Mengci Hu, Wenzhe Li, Youshan Zhang, Caixia Liang, Jie Tan, Ya Wang
• Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 168 Pg. 115820 (Dec 2023) ISSN: 1950-6007 [Electronic] France
• PMID: 37925935 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Chemical References

• venetoclax
• Proto-Oncogene Proteins c-bcl-2
• Bridged Bicyclo Compounds, Heterocyclic

Topics

• Humans
• Adult
• Proto-Oncogene Proteins c-bcl-2 (metabolism)
• Apoptosis
• Leukemia, Myeloid, Acute (drug therapy, metabolism)
• Bridged Bicyclo Compounds, Heterocyclic (pharmacology, therapeutic use)